RxDoctor Payments Data

Armida Celeste Gavino, MD

Family Medicine · Pearland, TXNPI 1427671361

Payments from drug & device makers

$2,954in general payments, 2019–2025

Across 137 payments — averaging $21.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$381
  • Lilly USA, LLC$338
  • AbbVie$289
  • AstraZeneca$249
  • Pfizer$244
  • Novo Nordisk$240
  • plus $1K from 19 others

What the payments were for

  • Food & beverage$2,954100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,954 in reported general payments places this provider in the 75th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$18,479
Medicare patients
40
Services billed
243

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide47$48,635
OzempicSemaglutide18$17,128
JanuviaSitagliptin Phosphate12$12,626
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen12$854
Rosuvastatin Calcium17$305
Lisinopril44$249
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen16$244
Levothyroxine Sodium29$232
Amlodipine Besylate29$231
Gabapentin24$222
Losartan Potassium20$179
Paroxetine Hcl16$177
Pregabalin29$176
Metformin Hcl ErMetformin Hcl12$148
Sertraline Hcl28$138

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$338$48,63547 claims
Novo NordiskOzempic$240$17,12818 claims
MerckJanuvia$21$12,62612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Pearland

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →